Pharmacology and mechanisms of apigenin in preventing osteoporosis
Osteoporosis (OP) stands as the most prevalent systemic skeletal condition associated with aging. The current clinical management of OP predominantly depends on anti-resorptive and anabolic agents. Nevertheless, prolonged use of some of these medications has been observed to reduce efficacy and elev...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1486646/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846127347490619392 |
|---|---|
| author | Sun Lin Wang Yincang Du Jiazhe Xu Xilin Xiaofeng Zhang |
| author_facet | Sun Lin Wang Yincang Du Jiazhe Xu Xilin Xiaofeng Zhang |
| author_sort | Sun Lin |
| collection | DOAJ |
| description | Osteoporosis (OP) stands as the most prevalent systemic skeletal condition associated with aging. The current clinical management of OP predominantly depends on anti-resorptive and anabolic agents. Nevertheless, prolonged use of some of these medications has been observed to reduce efficacy and elevate adverse effects. Given the necessity for sustained or even lifelong treatment of OP, the identification of drugs that are not only effective but also safe and cost-efficient is of utmost significance. As disease treatment paradigms continue to evolve and recent advancements in OP research come to light, certain plant-derived compounds have emerged, presenting notable benefits in the management of OP. This review primarily explores the pharmacological properties of apigenin and elucidates its therapeutic mechanisms in the context of OP. The insights provided herein aspire to offer a foundation for the judicious use of apigenin in forthcoming research, particularly within the scope of OP. |
| format | Article |
| id | doaj-art-f99f2e7eb6794e8091785a8088c33189 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-f99f2e7eb6794e8091785a8088c331892024-12-12T04:29:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-12-011510.3389/fphar.2024.14866461486646Pharmacology and mechanisms of apigenin in preventing osteoporosisSun Lin0Wang Yincang1Du Jiazhe2Xu Xilin3Xiaofeng Zhang4Second Affiliated Hospital of Heilongjiang, University Of Chinese Medicine, Harbin, ChinaSecond Affiliated Hospital of Heilongjiang, University Of Chinese Medicine, Harbin, ChinaThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaThe Third Affiliated Hospital of Heilongjiang, University of Chinese Medicine, Harbin, ChinaSecond Affiliated Hospital of Heilongjiang, University Of Chinese Medicine, Harbin, ChinaOsteoporosis (OP) stands as the most prevalent systemic skeletal condition associated with aging. The current clinical management of OP predominantly depends on anti-resorptive and anabolic agents. Nevertheless, prolonged use of some of these medications has been observed to reduce efficacy and elevate adverse effects. Given the necessity for sustained or even lifelong treatment of OP, the identification of drugs that are not only effective but also safe and cost-efficient is of utmost significance. As disease treatment paradigms continue to evolve and recent advancements in OP research come to light, certain plant-derived compounds have emerged, presenting notable benefits in the management of OP. This review primarily explores the pharmacological properties of apigenin and elucidates its therapeutic mechanisms in the context of OP. The insights provided herein aspire to offer a foundation for the judicious use of apigenin in forthcoming research, particularly within the scope of OP.https://www.frontiersin.org/articles/10.3389/fphar.2024.1486646/fullapigeninosteoporosisoxidative stressosteoblastsinflammatory factors |
| spellingShingle | Sun Lin Wang Yincang Du Jiazhe Xu Xilin Xiaofeng Zhang Pharmacology and mechanisms of apigenin in preventing osteoporosis Frontiers in Pharmacology apigenin osteoporosis oxidative stress osteoblasts inflammatory factors |
| title | Pharmacology and mechanisms of apigenin in preventing osteoporosis |
| title_full | Pharmacology and mechanisms of apigenin in preventing osteoporosis |
| title_fullStr | Pharmacology and mechanisms of apigenin in preventing osteoporosis |
| title_full_unstemmed | Pharmacology and mechanisms of apigenin in preventing osteoporosis |
| title_short | Pharmacology and mechanisms of apigenin in preventing osteoporosis |
| title_sort | pharmacology and mechanisms of apigenin in preventing osteoporosis |
| topic | apigenin osteoporosis oxidative stress osteoblasts inflammatory factors |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1486646/full |
| work_keys_str_mv | AT sunlin pharmacologyandmechanismsofapigenininpreventingosteoporosis AT wangyincang pharmacologyandmechanismsofapigenininpreventingosteoporosis AT dujiazhe pharmacologyandmechanismsofapigenininpreventingosteoporosis AT xuxilin pharmacologyandmechanismsofapigenininpreventingosteoporosis AT xiaofengzhang pharmacologyandmechanismsofapigenininpreventingosteoporosis |